EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May 22, 2017--
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in
vitro diagnostic technologies to the healthcare industry, today
announced that Gary Maharaj, president and chief executive officer, and
Andy LaFrence, vice president of finance and information systems and
chief financial officer, will be attending two upcoming investor
On Wednesday, May 24, 2017, at 12:30 p.m. PT (2:30 p.m. CT), company
management will make a presentation at the B. Riley 2017 Institutional
Investors Conference in Santa Monica, California.
On Tuesday, June 6, 2017, at 1:30 p.m. ET (12:30 p.m. CT), company
management will make a presentation at the Jefferies Healthcare
Conference in New York City.
Live audio webcasts of the presentations can be accessed by going to the
investor relations portion of the Company’s website at www.surmodics.com
and clicking on the webcast icon. Webcasts will be archived on the
Company’s website for 90 days.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for
intravascular medical devices and a leading provider of chemical
components for in vitro diagnostic (IVD) tests and microarrays.
Following two recent acquisitions of Creagh Medical and NorMedix, the
Company is executing a key growth strategy for its medical device
business by expanding to offer total intravascular product solutions to
its medical device customers. The combination of proprietary surface
technologies, along with enhanced device design, development and
manufacturing capabilities, enables Surmodics to significantly increase
the value it offers with highly differentiated intravascular solutions
designed and engineered to meet the most demanding requirements. With
this focus on offering total solutions, Surmodics’ mission remains to
improve the detection and treatment of disease. Surmodics is
headquartered in Eden Prairie, Minnesota. For more information about the
company, visit www.surmodics.com.
The content of Surmodics’ website is not part of this press release or
part of any filings that the company makes with the SEC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005275/en/
Source: Surmodics, Inc.
Andy LaFrence, 952-500-7000